Four London teaching hospitals concentrate roughly 6,000 of the UK's 15,000-17,000 sickle cell patients, and NHS England's planned 6-8 JACIE-accredited gene-therapy hubs will further concentrate institutional influence around a small number of transplant-capable centres.
UK sickle cell disease expertise concentrates around a defined set of specialist centres, not a broad national field. Four London teaching hospitals, Barts, King's, Imperial, and Homerton, treat a combined estimated 6,000 patients out of the UK's 15,000-17,000 total; Birmingham Heartlands treats a further 2,000, with Manchester, Bristol, and Nottingham forming the next concentration ring. That kind of geographic clustering does not happen without an established referral network between paediatric and adult haematology services. Our KOL Universe gate (K1) starts by mapping exactly this institutional concentration before any individual physician is scored.
That structure changes how AXLRx tiers influence across the UK network. A haematologist affiliated with one of the eight named centres, especially one active on the British Society for Haematology's SCD guideline committee or engaged with the Sickle Cell Society UK on NICE patient-group submissions, carries different scientific weight than one working outside that structure, and our Tier Classification gate (K2) scores that distinction directly, alongside NICE TA1044 managed-access site designation and transfusion-programme role. No named individual enters the workbook without a verification tag; every KOL identity is checked against live publication records and institutional affiliations, then marked Verified, Industry benchmark, or Requires client validation. A commercial team engaging the wrong tier wastes MSL capacity on a centre with no real influence over NHS England's gene-therapy hub selection, which is exactly what the K1-K6 gate structure is built to prevent.
The UK sickle cell disease centre network — eight named institutions across five cities
| Institution | City | Estimated Patients / Role |
|---|---|---|
| Barts Health NHS Trust | London | Part of the ~6,000-patient combined London cohort |
| King's College Hospital | London | Part of the ~6,000-patient combined London cohort |
| Imperial College Healthcare NHS Trust | London | Part of the ~6,000-patient combined London cohort |
| Homerton University Hospital | London | Part of the ~6,000-patient combined London cohort |
| Birmingham Heartlands Hospital | Birmingham | Roughly 2,000 patients |
| Manchester specialist centre | Manchester | Regional referral centre |
| Bristol specialist centre | Bristol | Regional referral centre |
| Nottingham specialist centre | Nottingham | Regional referral centre |
Sources: NHS SCD Programme 2023; NHS SCD audit 2022; British Society for Haematology hydroxycarbamide guideline, 2018; NICE technology appraisal TA1044 (Casgevy, February 2025); NHS England SCD gene therapy planning 2024.
What this workbook answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- The eight-centre UK concentration structure
- the London, Birmingham, Manchester, Bristol, and Nottingham referral network
- K1 KOL Universe Sizing methodology
Delivers
- K2 Tier Classification methodology
- guideline-committee and NICE managed-access-site weighting
- K3 Scientific Influence scoring inputs
Delivers
- The three-tag verification protocol (Verified/Industry benchmark/Requires client validation)
- live publication and institutional-affiliation cross-checks
- why no placeholder name ships unflagged
Custom workbook delivered in 72 hours.
Commission This WorkbookWhat's inside
- Why institutional concentration, not scattergun individual outreach, is the single variable this workbook sizes first
- Pressure-tested against the eight-centre UK referral structure before the rest of the workbook is built out
- Every UK sickle cell disease KOL sized and sourced from publication and institutional-affiliation data
- The London, Birmingham, Manchester, Bristol, and Nottingham centre network as the sizing anchor
- Universe boundaries: who counts as a KOL versus a high-volume prescriber
- Scientific-influence scoring across guideline-committee membership and NICE managed-access-site role
- What separates a Tier 1 KOL from a high-volume community haematologist
- Influence inputs: guideline authorship, transfusion-programme leadership, institutional role
- Cross-checked against independent publication and citation data
- Readiness scoring and channel recommendations per KOL
- Sequencing implications for MSL deployment
- Territory-to-KOL coverage map across London, Birmingham, Manchester, Bristol, and Nottingham
- Where current MSL deployment has gaps
- UK KOLs active on European or international sickle cell disease guideline bodies
- Implications for coordinated versus purely local engagement
- The open KOL-engagement questions your medical affairs team must close
- Structured for an internal alignment session before MSL deployment
Included with every brief
How AXLRx builds this workbook
Prepared by MoatRx analysts.
Every AXLRx KOL workbook is built from live publication records and institutional-affiliation data, not secondary summaries. No KOL name ships without a verification tag.
UK sickle cell disease KOL sources: NHS SCD Programme annual reporting, the NHS SCD audit 2022, British Society for Haematology guideline documentation, and NICE TA1044 managed-access site designations.
- Centre list and combined London patient estimate verified against NHS SCD Programme 2023 and the NHS SCD audit 2022
- NICE TA1044 managed-access hub planning figures verified against NHS England SCD gene therapy planning 2024
- Every KOL entry in the underlying workbook carries a three-tag verification status before delivery: Verified, Industry benchmark, or Requires client validation
Frequently asked questions
Commission this workbook
AXLRx delivers KOL mapping workbooks built for medical affairs and commercial teams engaging UK sickle cell disease specialists. Custom workbook in 72 hours.
Specify your indication, geography, and institution scope.
AXLRx analyst confirms institution scope and verification standard before building.
Research-verified KOL workbook in 72 hours with optional analyst readout.